Last updated: September 9, 2026
Cutaquig, the U.S. brand for immune globulin subcutaneous (human)-hipp, is Octapharma AG’s subcutaneous immunoglobulin product for primary immunodeficiency diseases. FDA approved the product on October 13, 2018, under biologics license application 761180. Its commercial profile is driven by the expanding plasma-derived immunoglobulin market, conversion from hospital-administered intravenous immunoglobulin, home-infusion adoption, and Octapharma’s manufacturing capacity.
Octapharma does not publicly report Cutaquig revenue as a separate line item. The product’s financial performance therefore must be assessed through company-level revenue, market positioning, utilization growth, and competitive share rather than audited product sales.
What is immune globulin subcutaneous (human)-hipp?
Immune globulin subcutaneous (human)-hipp is a 16.5% human immunoglobulin G solution marketed in the United States as Cutaquig. It is administered subcutaneously through an infusion pump for patients with primary immunodeficiency diseases requiring immunoglobulin replacement therapy.[1]
| Attribute |
Cutaquig |
| Active ingredient |
Human normal immunoglobulin G |
| U.S. brand |
Cutaquig |
| Nonproprietary name |
Immune globulin subcutaneous (human)-hipp |
| Sponsor |
Octapharma AG |
| U.S. BLA |
761180 |
| FDA approval |
October 13, 2018 |
| Dosage form |
16.5% subcutaneous solution |
| Main indication |
Primary immunodeficiency diseases |
| Administration |
Subcutaneous infusion |
| Product class |
Plasma-derived biologic |
| U.S. regulatory pathway |
351(a) biologics license application |
Cutaquig contains predominantly IgG with a distribution of subclasses corresponding broadly to normal human plasma. Its formulation is designed for repeated home administration, which differentiates it from intravenous immunoglobulin products that are commonly administered in infusion centers or hospitals.
How large is the subcutaneous immunoglobulin market?
The subcutaneous immunoglobulin market is a growing segment of the broader immunoglobulin replacement market. Growth comes from greater diagnosis of primary immunodeficiency, increased treatment duration as patients remain on replacement therapy, home-care adoption, and physician preference for avoiding venous access.
The market has several structural constraints:
- Human plasma is the primary raw material.
- Manufacturing requires fractionation, purification, viral clearance, and extensive quality testing.
- Plasma collection capacity limits supply growth.
- Payers often manage immunoglobulin products through specialty-pharmacy and home-infusion channels.
- Switching can be clinically and operationally difficult once patients are stable on a product.
Cutaquig competes in a market with high barriers to entry but established multinational competitors. The leading products include Hizentra, HyQvia, Xembify and Gamunex-C.
| Product |
Company |
Delivery route |
Main commercial position |
| Cutaquig |
Octapharma |
Subcutaneous |
Direct SCIG competitor with home-infusion positioning |
| Hizentra |
CSL Behring |
Subcutaneous |
Large established SCIG franchise |
| HyQvia |
Takeda |
Facilitated subcutaneous |
Uses recombinant human hyaluronidase to enable larger-volume infusions |
| Xembify |
Grifols |
Subcutaneous |
U.S. SCIG competitor |
| Gamunex-C |
Grifols |
Intravenous and subcutaneous |
Broad immunoglobulin replacement and immune-modulation franchise |
| Vivaglobin |
CSL Behring |
Subcutaneous |
Earlier SCIG product, with market history preceding Hizentra |
What is Cutaquig’s financial trajectory?
Cutaquig’s revenue is not separately disclosed by Octapharma. The company is privately held and reports consolidated financial information rather than brand-level sales for individual immunoglobulin products.
Octapharma reported group revenue of approximately €3.3 billion in 2023, reflecting its position in human proteins, hematology, immunotherapy and critical-care products.[2] That figure includes Cutaquig only as part of the broader Octapharma portfolio.
Revenue drivers
Cutaquig’s commercial trajectory depends on five factors:
- Conversion of patients from intravenous immunoglobulin to home-based subcutaneous therapy.
- New primary immunodeficiency diagnoses.
- Reimbursement coverage for home infusion and specialty pharmacy.
- Reliable access to immunoglobulin supply.
- Octapharma’s ability to secure plasma and expand fractionation capacity.
The product has a recurring-revenue profile because primary immunodeficiency patients generally require long-term replacement therapy. Revenue is therefore more dependent on patient retention, dosing intensity and supply availability than on one-time launches.
Financial advantages
Cutaquig has several economic advantages relative to a newly launched small-molecule drug:
- Chronic treatment creates recurring demand.
- Biologic manufacturing capacity limits direct generic substitution.
- Patient switching may require clinical monitoring and infusion training.
- Home administration can reduce facility-based infusion costs.
- The product fits Octapharma’s existing plasma and specialty-care infrastructure.
Its principal financial limitation is the absence of a publicly reported standalone P&L. Investors cannot directly calculate Cutaquig revenue, gross margin or contribution profit from Octapharma’s public disclosures.
When does Cutaquig lose biologic exclusivity?
Cutaquig received 12 years of U.S. reference-product exclusivity under the Public Health Service Act. Based on the October 13, 2018 approval date, the statutory reference-product exclusivity period runs to October 13, 2030, subject to the precise statutory treatment of the product’s first licensure and any regulatory adjustments.[3]
A biosimilar application may generally be submitted four years after the reference product’s first licensure. For Cutaquig, that submission window opened in October 2022. FDA approval of a biosimilar cannot take effect before the end of the 12-year reference-product exclusivity period, absent a separate legal basis for earlier approval or market entry.
| U.S. milestone |
Date |
| Cutaquig BLA approval |
October 13, 2018 |
| Earliest general biosimilar submission window |
October 13, 2022 |
| Expected end of 12-year reference-product exclusivity |
October 13, 2030 |
| Potential post-2030 competition |
Biosimilar or other follow-on biologic products, subject to FDA approval and patent rights |
Exclusivity is distinct from patent protection. A biosimilar may be approved after the regulatory exclusivity period but remain subject to patent litigation, licensing restrictions or a negotiated launch date.
What is the Orange Book and Purple Book status of Cutaquig?
Cutaquig is a biologic and is not regulated through the conventional small-molecule Orange Book framework. The FDA’s Purple Book is the relevant database for licensed biological products, reference products, biosimilars and interchangeable biosimilars.[4]
The absence of an Orange Book patent listing means that a generic manufacturer cannot use a conventional Abbreviated New Drug Application and Paragraph IV certification to challenge Cutaquig in the manner used for small-molecule drugs.
| Issue |
Cutaquig status |
| Orange Book listing |
Not the applicable biologic framework |
| Purple Book relevance |
Yes |
| ANDA pathway |
No |
| Paragraph IV certification |
No conventional Paragraph IV pathway |
| Biosimilar pathway |
Potential 351(k) pathway |
| Reference-product exclusivity |
Twelve years from first licensure, subject to statutory interpretation |
| Interchangeability |
No automatic interchangeability based solely on product approval |
Are there Paragraph IV challenges to Cutaquig?
No conventional Paragraph IV challenge applies to Cutaquig. Paragraph IV litigation is associated with the Hatch-Waxman framework for small-molecule products and ANDAs. A biosimilar applicant instead follows the Biologics Price Competition and Innovation Act patent-dispute process, commonly called the patent dance.
A biosimilar sponsor may exchange information with the reference-product sponsor, identify patents that may be asserted, and negotiate or litigate before commercial launch. The process does not produce an Orange Book-style public certification record.
No publicly established Cutaquig Paragraph IV litigation framework exists because Cutaquig is not an ANDA product.
What patents protect Cutaquig?
Cutaquig’s protection is likely to involve a combination of:
- Formulation patents.
- Manufacturing and purification patents.
- Product-quality and stability claims.
- Infusion or administration methods.
- Device or container claims, where applicable.
- Trade secrets covering plasma fractionation, purification and quality control.
FDA does not publish an Orange Book-style, sponsor-certified patent list for Cutaquig. The BLA record also does not provide a complete, authoritative patent-expiration table. As a result, the 2030 regulatory exclusivity date should not be treated as the final possible market-entry date.
Formulation and manufacturing barriers
The strongest practical protection may come from manufacturing complexity rather than a single composition patent. Immunoglobulin products require:
- Large-scale plasma sourcing.
- Fractionation and purification.
- Viral inactivation and removal.
- Consistent IgG subclass distribution.
- Control of aggregates and impurities.
- Stability through shelf life.
- Batch-to-batch comparability.
- Compliance with biologics manufacturing standards.
A biosimilar sponsor would need to demonstrate high similarity to the reference product while building a separate plasma supply and manufacturing system. That requirement raises capital needs and limits the number of credible entrants.
What patent litigation affects Cutaquig?
There is no widely reported public Cutaquig patent litigation comparable to major small-molecule pharmaceutical cases. The key litigation risk is prospective rather than historical: a future biosimilar sponsor could trigger patent disputes before or after FDA approval.
Potential disputes would likely involve:
- Whether a formulation claim covers a proposed biosimilar.
- Whether a manufacturing process is practiced by the biosimilar sponsor.
- Whether the product has materially different glycosylation, aggregation or stability characteristics.
- Whether a method-of-use claim covers primary immunodeficiency treatment.
- Whether the biosimilar sponsor complied with BPCIA information-exchange requirements.
Which companies challenge Cutaquig commercially?
Cutaquig faces established competition rather than a near-term generic threat.
Hizentra versus Cutaquig
Hizentra, marketed by CSL Behring, has a mature commercial presence and strong physician and specialty-pharmacy relationships. Its competitive advantage is brand longevity and broad clinical familiarity. Cutaquig competes through Octapharma’s plasma infrastructure, product availability and home-infusion positioning.
HyQvia versus Cutaquig
HyQvia uses recombinant human hyaluronidase to permit larger-volume, less-frequent subcutaneous administration. Its value proposition is convenience and reduced infusion frequency. Cutaquig generally competes with a more conventional SCIG model, which can offer smaller, more frequent administrations and does not require a separate hyaluronidase component.
Xembify versus Cutaquig
Xembify is Grifols’ subcutaneous immunoglobulin product. Grifols has a large plasma-collection and immunoglobulin infrastructure, making supply reliability and contracting important competitive variables.
What generic and biosimilar launch risks exist?
The near-term generic-launch risk is low because Cutaquig is a biologic and cannot be substituted through an ANDA. The medium- and long-term risk is higher after October 2030, when statutory reference-product exclusivity is expected to end.
| Period |
Competitive risk |
| 2018-2022 |
Primarily branded competition; biosimilar submissions generally unavailable before four years |
| 2022-2030 |
Biosimilar development and possible patent litigation |
| After 2030 |
Potential biosimilar approvals, negotiated launches and payer-driven switching |
| Long term |
Price pressure depends on number of entrants, interchangeability and supply economics |
Actual erosion would probably be slower than the erosion experienced by many oral drugs. Immunoglobulin products are complex biologics, and payer substitution may be constrained by physician preference, patient tolerance, infusion logistics and supply contracts.
How strong is the Cutaquig patent estate?
Cutaquig has a strong commercial defense even if its publicly visible patent position is difficult to summarize in an Orange Book-style table. The principal strengths are:
- A 12-year biologic exclusivity period.
- Complex plasma-derived manufacturing.
- High regulatory and capital barriers.
- Limited global plasma supply.
- Long-term patient treatment patterns.
- Octapharma’s existing manufacturing platform.
The principal weaknesses are:
- No publicly disclosed standalone product revenue.
- Competition from several established SCIG brands.
- Potential biosimilar development before the end of regulatory exclusivity.
- Dependence on plasma supply and manufacturing uptime.
- Limited ability to use patent-based substitution controls in the same way as an Orange Book-listed small molecule.
What licensing deals affect Cutaquig?
No major publicly disclosed licensing transaction is required to explain Cutaquig’s U.S. commercial position. Octapharma owns and markets the product through its own organization. The product’s economics are linked more closely to internal plasma sourcing, fractionation and distribution than to a publicly announced external technology license.
The relevant strategic asset is Octapharma’s integrated human-protein platform. That platform can support manufacturing, regulatory compliance and specialty distribution across multiple immunoglobulin products.
What is the FDA regulatory status of Cutaquig?
Cutaquig is FDA-approved for primary immunodeficiency diseases. Its approval does not establish approval for every immunoglobulin-responsive disorder, and use outside the labeled indication would depend on clinical judgment and applicable reimbursement rules.[1]
The product’s regulatory risk is moderate. FDA oversight focuses on product consistency, sterility, viral safety, immunogenicity, potency, stability and manufacturing controls. For plasma-derived products, a supply disruption or manufacturing deviation can affect commercial performance more immediately than ordinary patent events.
How does Cutaquig compare with competing immunoglobulin products?
| Factor |
Cutaquig |
Hizentra |
HyQvia |
Xembify |
| Route |
Subcutaneous |
Subcutaneous |
Facilitated subcutaneous |
Subcutaneous |
| Manufacturer |
Octapharma |
CSL Behring |
Takeda |
Grifols |
| Home administration |
Yes |
Yes |
Yes |
Yes |
| Hyaluronidase required |
No |
No |
Yes |
No |
| Commercial maturity |
Established |
Highly established |
Established |
Established |
| Main differentiation |
Conventional SCIG and Octapharma supply platform |
Brand scale and physician familiarity |
Larger-volume, less-frequent infusion |
Grifols plasma and immunoglobulin platform |
| Biosimilar exposure |
Potential after exclusivity period |
Potential after exclusivity period |
More complex product architecture |
Potential after exclusivity period |
What is the outlook for Cutaquig revenue?
Cutaquig should maintain a recurring-growth profile through the end of the decade if Octapharma sustains supply and expands payer access. The main revenue opportunity is share capture in the growing home-based SCIG segment rather than a sharp price increase.
Revenue growth is likely to be shaped by:
- Patient additions.
- Conversion from intravenous therapy.
- Greater use of home infusion.
- Contract wins with specialty pharmacies and payers.
- Product availability during immunoglobulin shortages.
- Competitive pricing.
- Manufacturing expansion.
The principal post-2030 threat is not an immediate collapse in sales. It is gradual price and share pressure from biosimilars, new facilitated-SCIG products, and payer-directed substitution. Octapharma’s manufacturing scale and supply reliability will determine whether Cutaquig retains premium access after regulatory exclusivity expires.
Key Takeaways
- Cutaquig is Octapharma’s 16.5% subcutaneous immunoglobulin product, approved by FDA in 2018.
- Octapharma does not disclose Cutaquig revenue separately, so product-level financial performance cannot be calculated from public company filings.
- The product benefits from recurring primary-immunodeficiency demand and home-infusion adoption.
- Its expected U.S. biologic reference-product exclusivity runs to October 2030.
- Paragraph IV litigation does not apply because Cutaquig is a biologic, not an Orange Book small-molecule product.
- Future biosimilar competition would proceed under the BPCIA and Purple Book framework.
- Manufacturing complexity, plasma supply and quality controls provide major barriers to entry.
- Hizentra, HyQvia, Xembify and other immunoglobulin products are the principal commercial competitors.
- The most likely financial outcome is continued growth before 2030, followed by gradual competitive pressure rather than immediate generic-style erosion.
FAQs About Cutaquig Exclusivity and Market Competition
Is Cutaquig the same as Hizentra?
No. Both are subcutaneous immunoglobulin products, but they are manufactured by different companies and are not automatically interchangeable.
Can pharmacies automatically substitute a biosimilar for Cutaquig?
No. Automatic substitution would depend on FDA interchangeability status, state substitution laws, payer rules and the specific product’s approval.
Does Cutaquig have an Orange Book patent listing?
No conventional Orange Book listing applies because Cutaquig is a biologic regulated under the Public Health Service Act.
What is the main commercial risk to Cutaquig before 2030?
The principal risks are competing SCIG products, payer contracting, immunoglobulin supply constraints and manufacturing interruptions rather than conventional generic substitution.
Will Cutaquig lose all exclusivity in 2030?
No. The expected end of reference-product exclusivity in 2030 does not eliminate patents, manufacturing know-how, trade secrets, supply advantages or brand-based commercial protections.
References
- U.S. Food and Drug Administration. (2018). Cutaquig prescribing information.
- Octapharma AG. (2024). Annual report 2023.
- Public Health Service Act, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
